Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma.
Krishnan A, Nooka AK, Chari A, Garfall AL, Martin TG, Nair S, Lin X, Qi K, Londhe A, Pei L, Ammann E, Kobos R, Smit J, Parekh T, Marshall A, Slavcev M, Usmani SZ.
Krishnan A, et al. Among authors: lin x.
J Comp Eff Res. 2023 Jun;12(6):e220186. doi: 10.57264/cer-2022-0186. Epub 2023 Apr 28.
J Comp Eff Res. 2023.
PMID: 37114426
Free PMC article.